Extension of the subscription granting access to the monographs, the comparative charts and the interaction analysis for 12 months (including monthly updates).
RxVigilance - a reference tool for health care professionals that features information on drugs and health - can now be accessed from anywhere.
After installation, THE APPLICATION RESIDES ENTIRELY ON THE DEVICE and does not require an Internet connection for regular use. Internet access is required for updates.
Already used by thousands of physicians, pharmacists, nurses and other health care professionals across Canada, RxVigilance provides you with relevant and up to date information from several dozen leading reference sources. Drug monographs, pharmacological profile analysis, and information on natural products and travel destinations are among some of the many features you can now access through your device.
Our team of health care professionals is well aware of your day to day information needs. As a result, they are equipped to select what is most useful and relevant for you and your practice and to integrate that information to RxVigilance. In short, you will be able to access what you need quickly and effectively.
The RxVigilance Mobile App includes access to:
COMPARATIVE CHARTS
In the application users will find a series of charts comparing the characteristics of products from the same pharmacological class in order to help them make the best therapeutic decision based on onset of action or the number of administrations a day, for example.
MONOGRAPHS
Professional information on more than 1200 drugs. You can find information on adverse reactions, official and unofficial indications, adult dosages, pediatric dosages, geriatric dosages, adjustments for renal and hepatic impairment, precautions in pregnancy/breastfeeding, special precautions (grapefruit, stability, food, etc.), contraindications, interactions and kinetics. Monographs are regularly updated with information deemed relevant by our team of professionals.
TRAVEL
This feature allows to search for over 200 destinations. It provides access to brief and relevant overview of the destination (currency, languages, population, capital), required and/or recommended immunizations by country, recommendations based on diseases found in each country and contact details for service centres that may be of use while traveling.
NATURAL PRODUCTS
Information on more than 60 of the most commonly used natural products. It includes product indications (classified by evidence of effectiveness), product description and discussion on product safety and efficacy.
PROFILE ANALYSIS
Profile analysis allows to identify interactions and provides a description of the interactions as well as recommendations. Interactions are classified by importance of actions to be taken by the professional.
BULLETINS
Monthly communiqué for subscribers with details on the most recent updates and new developments and a list of monographs to which changes have been made. It is possible to refer to bulletins from prior months and send questions or comments via e-mail to the Rx Vigilance team.
PHONE DIRECTORY
A phone directory that consists of over 6000 useful contacts such as: hospitals, CLSCs, support groups and self-help groups, pharmacies, pharmaceutical companies, etc. It allows users to dial phone numbers directly from their iPhone and to acces links to internet sites when available.
Show less
What's New in RxVigilance Mobile
2.0.115
November 20, 2024
December 2024
(monthly update)
Modifications to RxVigilance
=========================
Adjustments in dialysis
We have enhanced our monographs with a new section dedicated to dose adjustments for patients on hemodialysis and peritoneal dialysis. This addition complements the existing information on renal impairment and dialysis supplements, providing you with even more precise and tailored recommendations for these clinical situations.
You will see the Adjustment in dialysis section gradually appear in our monographs, located just below the Renal impairment section.
New monographs
=========================
Lebrikizumab (Ebglyss)